Lumida
/GOCO
⌘K
Gohealth Inc

Gohealth Inc

GOCO
$0.31USD+5.14%+0.01 today

MARKET CAP

9.9M

P/E (TTM)

FWD P/E

DAY RANGE

$0 – $0

52W RANGE

$0
$7

AI Summary

Stalk
Sell NowHigh

GOCO remains in a Stage 4 decline with persistent lower highs and lower lows under declining EMAs. Relief rallies into the 9/20/50EMA and 50DMA quickly reject, and volume clusters on down moves confirm supply dominance. Short-term trend is down, with no exhaustion visible, making selling now into any bounce the optimal execution posture.

  • Q4 ’24 revenue $389 M (+41% YoY) driven by operational efficiency
  • CAC $501/submission (–27% YoY) reflects improved marketing strategies
  • Q3 ’25 revenue $95 M down as focus shifted to quality over volume
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

GoHealth, Inc. (NASDAQ: GOCO) is a technology-driven health insurance marketplace that primarily facilitates Medicare enrollments, focusing on providing navigational support for consumers in choosing suitable Medicare Advantage plans. The company operates within a sector experiencing significant transitions due to demographic shifts towards an aging population and evolving regulatory landscapes. Following a significant restructuring and emergence from Chapter 11 bankruptcy, GoHealth has repositioned itself as a private entity—aiming to deepen consumer engagement and streamline its operations influenced by proprietary technology and an expanded agent network.

Bull says

  • Q4 ’24 revenue $389 M (+41% YoY) driven by operational efficiency
  • CAC $501/submission (–27% YoY) reflects improved marketing strategies
  • eTeleQuote deal added 54 k submissions, boosting enrollment pipeline
  • GoHealth Protect launch diversifies into life insurance for seniors
  • Strong earnings yield and profitability metrics signal undervaluation
  • Positive momentum and analyst earnings revisions support growth outlook

Bear says

  • Q3 ’25 revenue $95 M down as focus shifted to quality over volume
  • Negative cash flow $12.4 M in Q1 ’25 and $5 M in Q2 ’25 signals liquidity strain
  • Facing False Claims Act lawsuit, elevating regulatory and legal risk
  • Health plans tightening commissions may pressure future revenue
  • High leverage and short interest suggest investor skepticism and volatility
  • Heavy dependence on AEP cycles risks uneven annual revenues

Investment themes with GOCO

Health Insurers (MCOs) +0.24%

UNH · CVS · CI

Earnings Call · Q3 2024 · Mgmt. Guidance

Updated 09-08-2026neutral

Transcript signals

Bull points

  • Go Health's focus on delivering clarity and value to consumers, combined with its commitment to innovation, positions us exceptionally well for growth.
  • In the third quarter of 2024, Go Health achieved net revenues of $118.3 million, compared to $132 million in the same period last year. Internal captive agent submissions saw a 46% year-over-year increase, thanks to enhanced training, improved technology, and more targeted marketing efforts.
  • We are deploying cash to seize the significant opportunities ahead, which we believe will position us to maximize growth and capitalize on the outsized potential we see in the current environment.

Bear points

  • This growth was offset by a 46% decline in submissions from our GPS channel, which faced broader market pressures.
  • This led to a reduction in third quarter revenue of over $8.8 million and earnings by more than $7.8 million.
  • to be materially mitigated going into the annual enrollment period, despite our efforts, this situation continues to impact our financial performance.
Read full transcript analysis ›